Strata Critical Medical (SRTA) Q4 2025 earnings review
Transformational Quarter Marks a Pure-Play Medical Inflection
Strata Critical Medical's first full quarter following the divestiture of its Blade passenger business and the acquisition of Keystone Perfusion was a definitive success on the P&L. Revenue from continuing operations surged 83.5% YoY to $66.8M, absolutely crushing organic growth targets with a 35.3% increase in its legacy Logistics segment. The Keystone integration is already yielding fruit, contributing $17.6M in Clinical revenue and driving 40% of the sequential Logistics growth via cross-selling. Adjusted EBITDA expanded nearly 6x to $7.0M. However, the cash flow statement tells a messier story: operating cash flow remained deeply negative at $(8.3)M due to ballooning working capital and legacy settlement costs. Management's raised 2026 guidance—projecting up to $275M in revenue and a reversal to positive Free Cash Flow—suggests the heavy lifting of the transition is mostly behind them.
🐂 Bull Case
The end-to-end 'one call' strategy is validated. More than 40% of the sequential logistics revenue growth in Q4 was generated directly from Keystone's legacy clinical customers.
Stripped of the consumer-facing passenger business, Strata's Adjusted SG&A as a percentage of revenue plummeted to 13.4% in Q4 from 19.7% a year ago, proving the pure-play model scales highly profitably.
🐻 Bear Case
Despite reporting $7.0M in Adjusted EBITDA, Q4 Operating Cash Flow was $(8.3)M. A $5.7M increase in working capital and $9.6M in non-recurring items dragged on liquidity.
Accounts Receivable essentially doubled YoY from $19.8M to $40.0M. While growth accounts for some of this, taking on Keystone's billing cycles introduces new collection execution risks.
⚖️ Verdict: 🟢
Bullish. Strata has successfully executed a complex strategic pivot. If the 2026 guidance holds true, the transition from negative operating cash flow to generating $15-$22M in Free Cash Flow will act as a major catalyst.
Key Themes
Keystone Acquisition Scaling Rapidly
The Clinical segment (Transplant and Other Clinical) generated $17.6M in Q4—a massive jump from the $2.8M recorded in the half-month of Q3 post-acquisition. Furthermore, Clinical Gross Margin stood at a healthy 21.8%, immediately accretive to the overall corporate margin profile.
Regulatory Tailwinds Reshaping the Market
Macro regulatory shifts are directly benefiting Strata. New proposed regulations favor high-performing Organ Procurement Organizations (OPOs) and prioritize the utilization of medically complex organs, particularly Donation after Circulatory Death (DCD). In Q4, Strata won new business when an underperforming OPO was absorbed by an existing Strata customer.
War Chest for Consolidation
Strata ended the year with $61.2M in cash and short-term investments, plus a newly closed $30M asset-backed credit facility with JP Morgan (expandable to $50M). Management explicitly stated they are targeting actionable acquisitions at mid-single-digit EBITDA multiples to consolidate the highly fragmented medical logistics space.
Working Capital and Cash Burn
The core red flag in this print is the massive gap between P&L profitability and cash generation. Adjusted EBITDA was a positive $7.0M, but Operating Cash Flow was $(8.3)M. The $15.3M bridge consists of $9.6M in non-recurring legacy legal/transaction costs and a $5.7M build in working capital. Management must prove they can collect efficiently on their surging revenue base.
Joby Aviation Value Deterioration
The previously touted $125M value of the Blade passenger divestiture to Joby Aviation has shrunk. Realized losses from the sale of Joby short-term investments hit $5.2M for the year, proving that taking pre-revenue eVTOL stock as consideration carried significant downside risk.
Embracing High-Tech Preservation and NRP
The company's device-agnostic strategy remains a strong selling point. By offering advanced Normothermic Regional Perfusion (NRP) capabilities and supporting new tech like the OrganOx metra device, Strata is embedding itself deeper into the surgical and logistical workflow of transplant centers.
Other KPIs
Accelerating improvement. Down dramatically from 19.7% in Q4 2024. This 630 basis point reduction proves the thesis that shedding the consumer-focused Blade brand and passenger overhead would rapidly uncover the underlying cash-generating potential of the medical business.
Stable to slightly Accelerating. Consolidated gross margin expanded 80 basis points YoY from 20.8%. Both the legacy Logistics (21.5%) and new Clinical (21.8%) segments are operating in tight, profitable alignment.
Decelerating cash conversion. Receivables spiked 101% YoY compared to $19.8M at the end of 2024. While total FY25 revenue grew 34%, the disproportionate jump in receivables requires immediate monitoring for potential collection friction.
Guidance
Accelerating. Raised from previous early estimates. At the $267.5M midpoint, this implies a massive 35.7% YoY growth rate over 2025's $197.1M, driven by a full year of Keystone contribution and continued organic market share gains.
Accelerating. The $31M midpoint represents a 120% jump over 2025's $14.1M. This implies roughly an 11.6% full-year margin, showing sequential stability from Q4 2025's exit velocity of 10.4%.
Reversing. A critical milestone for the company. After burning $(8.7)M in Free Cash Flow before aircraft purchases in Q4 2025, Strata expects to turn solidly cash flow positive for the full year 2026.
Key Questions
Working Capital Normalization
Accounts Receivable doubled YoY to $40M, while revenue grew 34%. How much of this is strictly related to Keystone integration timing versus structural changes in billing cycles, and when do we expect DSOs to normalize?
M&A Execution Capacity
You highlighted a robust pipeline for acquisitions at mid-single-digit EBITDA multiples. Given the heavy lifting still underway integrating Keystone, do you have the operational bandwidth to digest another major clinical or logistics asset in 2026?
Aircraft Capex Cadence
Your 2026 Free Cash Flow guidance explicitly excludes aircraft and engine acquisitions. With new geographies launching mid-year, what is the expected unadjusted CapEx burden for new dedicated fleet assets?